← All trials
NCT05063422
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 18, 2021
- Primary completion
- Jan 17, 2022
- Completion date
- Jan 17, 2022
- First posted
- Oct 1, 2021
- Last posted
- Oct 1, 2021
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Altamash Institute of Dental MedicineLead sponsor
- Altamash Institute of Dental MedicineReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.